Pfizer tests new pill form in healthy volunteers to see how food and acid reducers affect drug levels

NCT ID NCT07563894

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This early-stage study in 16 healthy adults aims to compare how well a new film-coated tablet of the experimental drug PF-07799933 is absorbed versus an older tablet form. It also checks whether taking the drug with a high-fat meal or with an acid-reducing medication changes drug levels in the blood. The results will guide how the drug should be taken in future clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PF-07799933 and PF-07799544 (investigational drugs)
What this could lead to: If successful, this study will help determine the best way to take these drugs in future trials, potentially leading to more effective dosing instructions.
What could go wrong: This is a very early Phase 1 study in only 16 healthy people, not patients. It only measures drug levels in the blood, not whether the drugs work for any disease. Results may not apply to sick patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PHASE 1

Contacts and locations

Locations

Pfizer Clinical Research Unit - New Haven

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.